Roche’s Tecentriq notches win in breast cancer with U.S. approval

83

Roche won U.S. approval on Friday of its immunotherapy Tecentriq to treat a significant number of patients with triple-negative breast cancer, a development hailed by doctors as a promising advance in fighting the aggressive disease.

http://feeds.reuters.com/~r/reuters/healthNews/~3/24P2JloWKFA/roches-tecentriq-notches-win-in-breast-cancer-with-u-s-approval-idUSKCN1QP20C